
Helping clinicians care for patients and putting patients first are core values at CND Life Sciences, and they require going well beyond offering innovative diagnostic tools such as the Syn-One Test®.
Helping clinicians care for patients and putting patients first are core values at CND Life Sciences, and they require going well beyond offering innovative diagnostic tools such as the Syn-One Test®.
CND Life Sciences’ senior scientific advisors Dr. Christopher Gibbons and Dr. Roy Freeman and two members of CND’s scientific team, Todd Levine, MD, and Bailey Bellaire, presented the results of their study titled “Cutaneous Alpha-Synuclein Detection in Patients with Suspected Synucleinopathies” at the Pan American Parkinson’s Disease and Movement Disorders Congress last month in Miami.
Kendall Swanson started at CND Life Sciences as an intern in the summer before her senior year of college. She was studying psychology, and marketing wasn’t an obvious next step for her. However, CND
was introducing its flagship product to the market during a global pandemic and was looking for good talent to make an instant impact.
Drs. Pravin Khemani and Michael Elliot from Swedish Neuroscience Institute in Seattle, Washington, published a case study last month in Parkinsonism and Related Disorders that highlights the role of the Syn-One Test in distinguishing overlapping clinical phenotypes of synucleinopathies from non-synucleinopathies.
Medical Laboratory Professionals Week is celebrated each year during the last week of April “…to recognize laboratory professionals for their valuable contributions directly impacting clinical and public health,” according to the CDC.
The methodology behind the Synuclein-One Study, the largest study to date of cutaneous phosphorylated alpha-synuclein detection, was published this month in Biomarkers in Medicine by CND Life Sciences’ senior scientific advisors Dr. Christopher Gibbons and Dr. Roy Freeman and members of CND’s scientific team, Todd Levine, MD and Bailey Bellaire.
CND Life Sciences is pleased to announce the next webinar in our Tuesday Night Talks series. Todd Levine, MD, CND’s Co-Founder and Chief Medical Officer
welcomes special guest Stuart H. Isaacson, MD, FAAN, Director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, FL to discuss the role and importance of alpha-synuclein as a key
pathological marker.
The Syn-One Test is the first commercially available test of its kind, developed to aid in the diagnostic evaluation of patients who exhibit features suggestive of the family of neurodegenerative conditions
known as synucleinopathies.
More than 300 million people, or 5% of the worldwide population, are living with a rare disease, defined as a disease that affects fewer than 200,000 people at any given time. Those with rare diseases are often misdiagnosed or not diagnosed at all, which makes it nearly impossible to find the right care.
CND Life Sciences recently welcomed Senior Pathologist & Medical Director, Janine Feng, MD and Senior Pathologist, Dana Haydel, MD to our team. We’re excited to introduce these highly experienced physicians to help lead our clinical pathology, research, and innovation programs.